CN105085631A

CN105085631A - Polypeptide capable of specifically targeting HER2 protein and application of polypeptide

Info

Publication number: CN105085631A
Application number: CN201510583724.8A
Authority: CN
Inventors: 耿令令; 方巧君
Original assignee: National Center for Nanosccience and Technology China
Current assignee: National Center for Nanosccience and Technology China
Priority date: 2015-09-14
Filing date: 2015-09-14
Publication date: 2015-11-25
Anticipated expiration: 2035-09-14
Also published as: CN105085631B

Abstract

The invention relates to polypeptide capable of specifically targeting HER2 (human epidermal growth factor receptor 2) protein and an application of the polypeptide. The polypeptide is shown by the following general formula: X1X2X3X4X5LX6X7X8NPX9X10X11X12X13. The invention also relates to a nucleotide sequence for coding the polypeptide, and an expression vector for expressing the polypeptide, and host cells; and the invention also relates to the polypeptide, a bivalent or a multivalent formed by the polypeptide, and a pharmaceutical composition which is formed by the polypeptide serving as a targeting polypeptide, a preparation capable of killing cancer cells, and an imaging preparation, as well as applications of the polypeptide, the bivalent or the multivalent, and the pharmaceutical composition. The polypeptide provided by the invention can achieve a targeting effect on positive tumor cells of HER2, is strong in selectivity, can be prepared by adopting a chemical synthesis method, is high in purity, small in molecular weight and strong in specificity, and is free of immunogenicity, safe and reliable.

Description

A kind of polypeptide of special target HER2 albumen and application thereof

Technical field

The present invention relates to medicinal chemistry art, be specifically related to a peptide species, particularly relate to a kind of polypeptide and application thereof of special target HER2 albumen.

Background technology

Cancer is the major causes of death in the whole world, data presentation: the newly-increased about 1,410 ten thousand routine cases of cancers in the whole world in 2012, number of cancer deaths reaches 8,200,000, and by comparison, the data of 2008 are respectively 1,270 ten thousand and 7,600,000.The most common cancer of diagnosis is followed successively by lung cancer (1,800,000 in world wide, 13%), mammary cancer (1,700,000,11.9%) and colorectal cancer (1,400,000,9.7%), main lethal cancer is lung cancer (1,600,000,19.4%), liver cancer (800,000,9.1%) and cancer of the stomach (700,000,8.8%).International cancer research institution estimates according to available data, and because population in the world increases and aging, before 2025, the annual newly-increased cancer number of cases in the whole world will up to 1,930 ten thousand examples.2012, cancer new cases over half and the number of cancer deaths of whole world sum occurred in low developed area, are respectively 56.8% and 64.9%.

The methods for the treatment of of current malignant tumour mainly contains operative treatment, chemotherapy, radiotherapy three kinds, and wherein chemotherapy is method with fastest developing speed in oncotherapy in recent years.But chemotherapeutics is while killing tumor cell, also killed and wounded human normal cell, toxic side effect is large.Therefore, anti-tumor drugs targeting and molecular probe research imperative.

The successful prerequisite of targeting cancer therapy is the target spot of finding treatment accurately.HER2 (human epidermal growth factor receptor 2 has another name called ErbB2) albumen is the transmembrane glycoprotein receptor tyrosine kinase of a 185kDa, is positioned cytolemma, has the outer ligand binding domain of born of the same parents, single membrane span district and Bao Nei tyrosine kinase activity district.HER2 participates in signal transduction pathway, causes phosphorylating kinase cascade reaction after activation, causes Growth of Cells and differentiation.Mammary cancer, ovarian cancer, have the overexpression of HER2 in the kinds of tumors such as cancer of the stomach and uterus.HER2 has become the important target of Therapeutic cancer.

Polypeptide is easy to a large amount of synthesis, and molecular weight is little, and tissue permeability is strong, can prevent the non-specific uptake of reticuloendothelial system simultaneously.In addition, polypeptide can be chemically modified to change its avidity, electric charge, hydrophobicity, stability and solvability, uses in vivo by optimization amendment repeatedly.In cancer target therapy, polypeptide drug and diagnostic probe demonstrate very strong superiority, are the attractive surrogates of one of antibody.In application aspect, polypeptide coordinates with radionuclide, can be used as probe application in molecular imaging; Some naturally occurring polypeptide are used as agent delivery; Peptide and their derivative of reproductive hormone can be used for neoplasm targeted therapy.Therefore high-level efficiency finds that valuable active polypeptide has become cancer diagnosis and treated the vital task faced.

CN104130315A discloses a kind of polypeptide of special target HER2 (human epidermal growth factor receptor 2) albumen, and described polypeptide is as shown in following general formula: X ₁x ₂x ₃x ₄x ₅x ₆x ₇rX ₈yWX ₉x ₁₀x ₁₁x ₁₂x ₁₃x ₁₄x ₁₅x ₁₆x ₁₇rX ₁₈x ₁₉x ₂₀x ₂₁yX ₂₂, targeting can be played to HER2 positive cell.Although it discloses this polypeptide to be used for the treatment of cancer there is targeting, but its interaction be combined with HER2 is not high enough, and targeting is also relatively poor.

Summary of the invention

The object of the present invention is to provide a peptide species, the polypeptide of special target HER2 albumen and an application thereof, particularly by this peptide derive and the purposes in target HER2 antitumor drug or video picture preparation can prepared with the protein bound product of HER2 and aforementioned polypeptides or its derived product.

For reaching this goal of the invention, the present invention by the following technical solutions:

First aspect, the invention provides a kind of peptide of target HER2 albumen, its aminoacid sequence general formula is: X ₁x ₂x ₃x ₄x ₅lX ₆x ₇x ₈nPX ₉x ₁₀x ₁₁x ₁₂x ₁₃

In above-mentioned peptide chain, the amino-acid residue of one-letter symbol representative is defined as follows: L is leucine, and N is l-asparagine, and P is proline(Pro), X _1-13for variable amino-acid residue.

As optimal technical scheme, X ₁be charge residue residue, be preferably Methionin or aspartic acid; X ₂be polar amino acid residues, be preferably Methionin, Threonine or tyrosine; X ₃be aromatic series or aliphatic amino acid residue, be preferably phenylalanine or Isoleucine; X ₄be aromaticity or heterocyclic amino acid residue, be preferably tyrosine or proline(Pro); X ₅be aromaticity or heterocyclic amino acid residue, be preferably tyrosine or proline(Pro); X ₆be aliphatic amino acid residue, be preferably glycine or L-Ala; X ₇be aliphatics or aromatic amino acid residue, be preferably leucine, tyrosine or tryptophane; X ₈be aromatic amino acid residue, be preferably tyrosine or tryptophane; X ₉be polar amino acid residues, be preferably Threonine or l-asparagine; X ₁₀be polar amino acid residues, be preferably Threonine or L-glutamic acid; X ₁₁be aromatic amino acid residue, be preferably tyrosine or tryptophane; X ₁₂be aromaticity or polar amino acid residues, be preferably phenylalanine, arginine or glutamine; X ₁₃be aromaticity or polar amino acid residues, be preferably tyrosine, Methionin or glutamine.

In the present invention, described polypeptide source is the peptide sequence DTCPPLMLYNPTTYQM based on HER2 homologous protein EGFR and the storage capacity set up is 2 × 10 ⁵polypeptide libraries:

The peptide sequence DTCPPLMLYNPTTYQM of EGFR forms EGFR-EGFR dimer, and the critical sites of EGFR-HER2 heterodimer, combines with HER2 protein extracellular II structural domain.Polypeptide of the present invention combines with HER2 extracellular region II structural domain, described polypeptide energy specific combination people HER2 high expression level positive breast cancer cells, and combination rate is more than 99%.

As optimal technical scheme, the aminoacid sequence of peptide of the present invention is selected from the aminoacid sequence shown in one of SEQIDNO.1-SEQIDNO.59.

Aminoacid sequence:

SEQ ID NO.1	DTFPYLGWWNPNEYRY
		SEQ ID NO.2	KTIYYLGYYNPNEYRY
SEQ ID NO.3	DYIPYLAYYNPNTYFQ
		SEQ ID NO.4	KKIPYLGWWNPTTWQQ
SEQ ID NO.5	DKFPYLALYNPTTWRQ
		SEQ ID NO.6	DKFPYLALYNPTTYFY
SEQ ID NO.7	DKFYPLGYYNPTEWFQ
		SEQ ID NO.8	DKFYYLAYWNPNEYRQ
SEQ ID NO.9	DTFPPLGWWNPTTWFY
		SEQ ID NO.10	DKFPPLGLYNPNEYFY
SEQ ID NO.11	DTFYYLAWWNPNEWRQ
		SEQ ID NO.12	DTFYYLGYWNPTTYRQ
SEQ ID NO.13	DTIYYLAWWNPTTWFY
		SEQ ID NO.14	DYFPPLGWYNPTTWFY
SEQ ID NO.15	DYFPPLGYYNPNEWQY
		SEQ ID NO.16	DYFPYLAWWNPNEWQQ
SEQ ID NO.17	DYFPYLAYWNPNEWQY
		SEQ ID NO.18	DYFPYLAYWNPNTWRY
SEQ ID NO.19	DYFPYLGLYNPNEWFY
		SEQ ID NO.20	DYFYYLAWWNPNEYFQ
SEQ ID NO.21	DYFYYLAWWNPTTWFQ
		SEQ ID NO.22	DYFYYLGYWNPNEYFY

SEQ ID NO.23	DYIPPLALWNPNEYFY
		SEQ ID NO.24	DYIPYLALWNPTTYFQ
SEQ ID NO.25	DKFPYLALWNPTTYFQ
		SEQ ID NO.26	DYIPYLAYYNPTEYFQ
SEQ ID NO.27	DYIYYLGLWNPTEYQQ
		SEQ ID NO.28	DYIYYLGLWNPTTWFY
SEQ ID NO.29	DYIYYLGYWNPTEWRK
		SEQ ID NO.30	DYIYYLGYYNPTTYQQ
SEQ ID NO.31	KKFPPLALYNPNTWFQ
		SEQ ID NO.32	KKFPPLGYYNPTEYRY
SEQ ID NO.33	KKFPYLAYWNPTTYRY
		SEQ ID NO.34	KKFPYLGYYNPTEYRQ
SEQ ID NO.35	KKFYPLGWWNPNEWRY
		SEQ ID NO.36	KKFYYLGYWNPNEWQY
SEQ ID NO.37	KKFYYLGYWNPNEWRQ
		SEQ ID NO.38	KKFYYLGYWNPNTWFQ
SEQ ID NO.39	KKIPPLAYYNPNTWFY
		SEQ ID NO.40	KKIPPLGWWNPNTWRY
SEQ ID NO.41	KKIPYLAWWNPTTYRQ
		SEQ ID NO.42	KKIPYLAYYNPNTWQQ
SEQ ID NO.43	DKFPYLALYNPTEWQQ
		SEQ ID NO.44	KKIYYLALWNPTEYRY

SEQ ID NO.45	KKIYYLAWWNPTEYFQ
		SEQ ID NO.46	KKIYYLGYYNPNEWRQ
SEQ ID NO.47	KKIYYLGYYNPTEWRQ
		SEQ ID NO.48	KTFYYLGWWNPNEWRQ
SEQ ID NO.49	KTFYYLGYWNPNEWQY
		SEQ ID NO.50	KTIPYLAWWNPNTWFQ
SEQ ID NO.51	DKFPPLGYWNPTTWQQ
		SEQ ID NO.52	KYFPPLGWWNPNTYQY
SEQ ID NO.53	KYFPPLGYWNPNTWQY
		SEQ ID NO.54	KYFPYLGWWNPTTWQY
SEQ ID NO.55	KYFYYLAYWNPTTYRQ
		SEQ ID NO.56	KYFYYLGLWNPNEWFQ
SEQ ID NO.57	KYIPPLAWWNPTEYQY
		SEQ ID NO.58	KYIPPLGWWNPTEYRY
SEQ ID NO.59	KYIYYLALYNPNTWRY

Second aspect, present invention also offers a kind of DNA fragmentation, and it comprises the aminoacid sequence of the peptide of coding the invention described above general formula.

As optimal technical scheme, described DNA fragmentation comprises the aminoacid sequence of the peptide of the described the present invention of coding as Suo Shi one of SEQIDNO.1-SEQIDNO.59.

The third aspect, present invention also offers a kind of expression vector, and the encoding amino acid sequence comprising at least one copy is the DNA fragmentation described in the second aspect present invention of peptide shown in general formula.

As optimal technical scheme, expression vector of the present invention, the encoding amino acid sequence comprising at least one copy is the DNA fragmentation described in the second aspect present invention of peptide shown in SEQIDNO.1-SEQIDNO.59.

Fourth aspect, present invention also offers a kind of protokaryon or eukaryotic host cell, and this host cell is containing, for example the expression vector described in third aspect present invention.

5th aspect, present invention also offers a kind of bivalent or multivalent, is assembled by peptide described in peptide described in the general formula 1 of first aspect present invention and SEQIDNO.1-SEQIDNO.59.

Bivalent as above or multivalent are the characteristic of the tumour cell with the target HER2 positive and have lethality to tumour cell.

As optimal technical scheme, bivalent of the present invention or multivalent be by connect molecule and/or the covalently bound formation of polymkeric substance or by with is connected molecule and/or mixed with polymers, non-covalent linking formation.

Preferably, described polymer is the mixing of any one or at least two kinds in polyoxyethylene glycol (PEG), polyvinyl alcohol (PVA), cyclodextrin, polyamidoamine dendrimer (PAMAM), poly(lactic acid) (PLA) or poly(lactic acid)-thanomin (PLGA).

6th aspect, the present invention still further provides a kind of pharmaceutical composition, the aminoacid sequence comprising first aspect present invention is peptide described in general formula, peptide as described in one of SEQIDNO.1-SEQIDNO.59 or as described in the bivalent of peptide or multivalent as target polypeptide, and the preparation of cancer cells can be killed and wounded.

As optimal technical scheme, peptide of the present invention, bivalent or multivalent, as target polypeptide, are puted together mutually with the preparation that can kill and wound cancer cells or mix.

Preferably, described preparation is any one that can kill and wound the chemicals of cancer cells, bio-pharmaceutical, Nano medication, radiopharmaceuticals, photo-thermal therapy or optical dynamic therapy medicine or wrap up in the carrier of these medicines;

Further preferably, described preparation is any one in alkylating agent, antimetabolite, antitumor natural drug, antitumor antibiotics, hormone and metal complex or tumour radiotherapy target marker.

Further preferably, described carrier is nano material, any one in liposome or oiliness compound, or the mixture be made up of multiple oiliness compound.

The present invention adopt by general formula as described in one of SEQIDNO.1-SEQIDNO.59 peptide and as described in the bivalent of peptide or multivalent and the macromolecular material such as nano material, liposome put together, the peptide that the present invention relates to, bivalent or multivalent can make the compound puting together rear generation more stably be transported to target cell in body.The peptide that the present invention relates to, bivalent or multivalent also can mix with the mixture of oiliness compound or multiple oiliness compound mutually, and the peptide that the present invention relates to also can make obtained mixture more stably be transported to target cell in body.

7th aspect, the present invention still further provides another pharmaceutical composition, the bivalent that the aminoacid sequence that described pharmaceutical composition comprises first aspect present invention is the peptide described in general formula described in peptide, SEQIDNO.1-SEQIDNO.59 or described peptide or multivalent; With video picture preparation.

Preferably, described peptide, bivalent or multivalent are puted together mutually with video picture preparation or are mixed.

Preferably, described video picture preparation is any one in radionuclide, radioisotope labeling thing or molecular image preparation.

Eighth aspect, the bivalent that the aminoacid sequence that present invention also offers first aspect present invention is the peptide described in general formula described in peptide, SEQIDNO.1-SEQIDNO.59 or described peptide or multivalent are for the preparation of the purposes in the medicine for the treatment of, prevention or diagnosing cancer or video picture preparation.

As optimal technical scheme, cancer of the present invention is the cancer of HER2 process LAN.

Preferably, described cancer is mammary cancer, lung cancer, cancer of the stomach, liver cancer, colon and rectum carcinoma, the esophageal carcinoma, leukemia, bladder cancer or cervical cancer.

Peptide of the present invention has the effect of target HER2 albumen, can as target head increase medicine or be loaded with medicine carrier as the content in HER2 positive cell such as nano material, liposome, then add pharmaceutically acceptable auxiliary material or novel more effective targeted anticancer medicine made by adjuvant.

Compared with prior art, the present invention has following beneficial effect:

(1) polypeptide of the present invention can play targeting to HER2 positive cell, and selectivity is strong, and polypeptide of the present invention can adopt the method for chemosynthesis to prepare, and purity is high, and molecular weight is little, high specificity, and non-immunogenicity is safe and reliable;

(2) polypeptide of the present invention can in conjunction with people HER2 positive breast cancer cells, combination rate is all more than 99%, very micro-with the keying action of HER2 low expression human embryo kidney (HEK) normal cell 293A cell, show the polypeptide of peptide of the present invention as special target HER2, to the selective keying action of HER2;

(3) polypeptide of the present invention has the characteristic of target HER2 positive tumor cell, also has characteristic tumour cell to lethality, as target polypeptide, can be used for the targeted therapy of tumour or the molecular imaging of target tumor and diagnosis.

Accompanying drawing explanation

Fig. 1 (A) is for flow cyctometry method detection control group 0.01mMPBS is to the actuating signal of people HER2 positive breast cancer cells (SKBR3 clone); Fig. 1 (B) detects fluorescein isothiocyanate (FITC) Anti-HER 2 that marks to the keying action of people HER2 positive breast cancer cells (SKBR3 clone) for flow cyctometry method; Fig. 1 (C) detects fluorescein isothiocyanate (FITC) SEQIDNO.1 that marks to the keying action of people HER2 positive breast cancer cells (SKBR3 clone) for flow cyctometry method; Fig. 1 (D) detects fluorescein isothiocyanate (FITC) SEQIDNO.2 that marks to the keying action of people HER2 positive breast cancer cells (SKBR3 clone) for flow cyctometry method; Fig. 1 (E) detects fluorescein isothiocyanate (FITC) SEQIDNO.3 that marks to the keying action of people HER2 positive breast cancer cells (SKBR3 clone) for flow cyctometry method; Fig. 1 (F) detects fluorescein isothiocyanate (FITC) SEQIDNO.4 that marks to the keying action of people HER2 positive breast cancer cells (SKBR3 clone) for flow cyctometry method; Fig. 1 (G) is combination rate histogram.

Fig. 2 (A) is for flow cyctometry method detection control group 0.01mMPBS is to the actuating signal of negative embryonic kidney normal cell (293A clone) of people HER2; Fig. 2 (B) is for the Anti-HER 2 of flow cyctometry method detection FITC mark is to the keying action of negative embryonic kidney normal cell (293A clone) of people HER2; Fig. 2 (C) is for the SEQIDNO.1 of flow cyctometry method detection FITC mark is to the keying action of negative embryonic kidney normal cell (293A clone) of people HER2; Fig. 2 (D) is for the SEQIDNO.2 of flow cyctometry method detection FITC mark is to the keying action of negative embryonic kidney normal cell (293A clone) of people HER2; What Fig. 2 (E) flow cyctometry method detected FITC mark is the keying action of SEQIDNO.3 to negative embryonic kidney normal cell (293A clone) of people HER2; Fig. 2 (F) is for the SEQIDNO.4 of flow cyctometry method detection FITC mark is to the keying action of negative embryonic kidney normal cell (293A clone) of people HER2; Fig. 2 (G) is combination rate histogram.

Fig. 3 is that immunofluorescence method detects SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 of FITC mark respectively to the keying action of people HER2 positive breast cancer cells (SKBR3 clone);

Wherein, nucleus hoechst reagent dyeing; A-D is the cell of SEQIDNO.1 polypeptide and hoechst process, and wherein A is the binding site of SEQIDNO.1 polypeptide, is mainly present in cytolemma, and B is nucleus, and C is the whole cell of bright field, and D is the superimposed figure of A-C; E-H is the cell of SEQIDNO.2 polypeptide and hoechst process, and wherein E is the binding site of SEQIDNO.2 polypeptide, is mainly present in cytolemma, and F is nucleus, and G is the whole cell of bright field, and H is the superimposed figure of E-G; I-L is the cell of SEQIDNO.3 polypeptide and hoechst process, and wherein I is the binding site of SEQIDNO.3 polypeptide, is mainly present in cytolemma, and J is nucleus, and K is the whole cell of bright field, and L is the superimposed figure of I-K; M-P is the cell of SEQIDNO.4 polypeptide and hoechst process, and wherein M is the binding site of SEQIDNO.4 polypeptide, is mainly present in cytolemma, and N is nucleus, and O is the whole cell of bright field, and P is the superimposed figure of M-O.

Fig. 4 is that immunofluorescence method detects SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 of FITC mark respectively to the keying action of negative embryonic kidney normal cell (293A clone) of people HER2;

Wherein, nucleus hoechst reagent dyeing; A-D is the cell of SEQIDNO.1 polypeptide and hoechst process, and wherein A is the binding site of SEQIDNO.1 polypeptide, and B is nucleus, and C is the whole cell of bright field, and D is the superimposed figure of A-C; E-H is the cell of SEQIDNO.2 polypeptide and hoechst process, and wherein E is the binding site of SEQIDNO.2 polypeptide, and F is nucleus, and G is the whole cell of bright field, and H is the superimposed figure of E-G; I-L is the cell of SEQIDNO.3 polypeptide and hoechst process, and wherein I is the binding site of SEQIDNO.3 polypeptide, and J is nucleus, and K is the whole cell of bright field, and L is the superimposed figure of I-K; M-P is the cell of SEQIDNO.4 polypeptide and hoechst process, and wherein M is the binding site of SEQIDNO.4 polypeptide, and N is nucleus, and O is the whole cell of bright field, and P is the superimposed figure of M-O.

Fig. 5 (A) is for surface plasma resonance (SPR) method detection SEQIDNO.1 is to the keying action of the people HER2 albumen of different concns; Fig. 5 (B) is for surface plasma resonance (SPR) method detection SEQIDNO.2 is to the keying action of the people HER2 albumen of different concns; Fig. 5 (C) is for surface plasma resonance (SPR) method detection SEQIDNO.3 is to the keying action of the people HER2 albumen of different concns; Fig. 5 (D) is for surface plasma resonance (SPR) method detection SEQIDNO.4 is to the keying action of the people HER2 albumen of different concns.

Embodiment

Further describe the present invention below in conjunction with specific embodiment, it will be understood by those skilled in the art that described embodiment is only that intended as illustrative illustrates the present invention, instead of intention limits the scope of the invention.Scope of the present invention is specifically limited by accompanying claim.

The synthesis of embodiment 1 polypeptide of the present invention

1) laboratory apparatus and material

Dimethyl formamide (DMF), piperidines, resin, methylene dichloride (DCM), ninhydrin reaction reagent (triketohydrindene hydrate, Vc, phenol), tetramethyl-urea hexafluorophosphate (HBTU), hexahydropyridine (piperidines), tri isopropyl silane (TIS), dithioglycol (EDT), anhydrous diethyl ether, trifluoroacetic acid (TFA), N-methylmorpholine (NMM), methyl alcohol, each seed amino acid, Solid-phase synthesis peptides pipe.

2) solution preparation

Deprotection liquid---hexahydropyridine: DMF=1:4

Reaction solution---NMM:DMF=1:24

Lysate---TFA (92.5%), TIS (2.5%), EDT (2.5%), H ₂o (2.5%)

Triketohydrindene hydrate test fluid---triketohydrindene hydrate: Vc: phenol=1:1:1

3) experimental procedure

Weigh resin also to put in Solid-phase synthesis peptides pipe (hereinafter referred to as reactor), add more than appropriate DMF swelling half an hour.Take out DMF, carry out Fmoc protective reaction with deprotection liquid, be placed in shaking table upper 10 minute.Take out protection liquid, wash 3 times with DMF, DCM, the resin that takes a morsel from reactor (about 5 ~ 10mg) is in test tube, and by washing with alcohol 2 times, ninhydrin method detects and records color, prepares to feed intake, and enters amino acid condensation and reacts.Get corresponding amino acid, HBTU (amino acid: HBTU=1:1) according to the aminoacid sequence order of SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 peptide respectively, dissolve with reaction solution, put in reactor, stirring reaction.After 1-2 hour, take a morsel resin from reactor in test tube, by washing with alcohol 2 times, ninhydrin method detects.Take out the liquid in reactor, respectively wash 2 times with DMF, DCM, obtain the peptide resin after first amino acid condensation.Above " Fmoc go protection---amino acid condensation " reactions steps is repeated to gained peptide resin, complete to the reaction of last amino acid, obtain the peptide that sequence number is SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4.After completion of the reaction, DMF, DCM each washing resin 2-3 time, methanol wash column twice, continues to drain 15-20 minute.The partial peptide resin synthesized is taken out, at room temperature in lysate (the first ice bath of lysate 20 minutes) middle cracking two hours in reactor.After resin filter, steaming instrument evaporate to dryness in revolving, washing 3 times with anhydrous diethyl ether (ice bath).Thick peptide uses preparative reverse HPLC-purified, uses HPLC to detect purity >90%.The pure peptide obtained uses mass spectrum (MS, electrospray) qualification.

To last peptide symthesis, take out part peptide resin and add fluorescein isothiocyanate (FITC) fluorescent mark.First be linked on polypeptide by amino acid couplings method by Fmoc-e-Acp-OH, then get appropriate HBTU and FITC and be dissolved in fluorescence coupling solvent, after 3-5 hours, triketohydrindene hydrate surveys solution testing.Marking successfully adopts above-mentioned same method to carry out cracking, purifying and qualification.

The relevant physicochemical character of SEQIDNO.1, SEQIDNO.2, SEQIDNO.3 and SEQIDNO.4 peptide as shown in Table 1 and Table 2.

Table 1

Table 2

Experimental example 1 flow cyctometry method detects SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 respectively to the keying action of people HER2 positive breast cancer cells

One, experimental technique

Collector mammary cancer HER2 overexpression cell line SKBR3, be suspended in the RPMI1640 nutrient solution containing 10% heat-inactivated fetal bovine serum, cell density is at 1x10 ⁶about/mL, is sub-packed in the EP pipe of four 1.5mL, and 200 μ L/ manage.Add SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 and Anti-HER 2 (ebioscience) that fluorescein isothiocyanate (FITC) marks respectively, ultimate density is 50 μMs/L, and the 0.01mMPBS (phosphoric acid buffer pH7.4) of control group with polypeptide equivalent replaces polypeptide.After lucifuge ice bath hatches 30 minutes, 1000g centrifugal 4 minutes collecting cells, add 1mLPBS cleaning, after repeated washing 3 times, add 500 μ LPBS, mixing, use flow cyctometry method fluorescence intensity and combining ratio.

Two, experimental result

As seen from Figure 1, SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 peptide can in conjunction with people HER2 high expression level breast cancer cell, and combination rate is all more than 99%, illustrate that peptide of the present invention is used alone and has affinity interaction to HER2 positive tumor cell, can use as the polypeptide of target HER2.

Experimental example 2 flow cyctometry method detects SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 respectively to the Normocellular keying action of the negative embryonic kidney of people HER2

One, experimental technique

Collector's embryonic kidney HER2 down-regulated express cell strain 293A, be suspended in the H-DMEM nutrient solution containing 10% heat-inactivated fetal bovine serum, cell density is at 1x10 ⁶about/mL, is sub-packed in four 1.5mLEP pipes.200 μ L/ manage.Add SEQIDNO.1, SEQIDNO.2 that fluorescein isothiocyanate (FITC) marks, SEQIDNO.3, SEQIDNO.4, Anti-HER 2 (ebioscience) respectively, ultimate density is 50 μMs of ol/L, and the 0.01mMPBS (phosphoric acid buffer pH7.4) of control group with polypeptide equivalent replaces polypeptide.After lucifuge ice bath hatches 30 minutes, 1000g centrifugal 4 minutes collecting cells, add 1mLPBS cleaning, after repeated washing 3 times, add 500 μ LPBS, mixing, use flow cyctometry method fluorescence intensity and combining ratio.

Two, experimental result

As seen from Figure 2, the keying action of SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 peptide and HER2 low expression human embryo kidney (HEK) normal cell 293A cell is very micro-, illustrate that peptide of the present invention is to the selective keying action of HER2, can use as the polypeptide of special target HER2.

Experimental example 3 immunofluorescence method detects SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 respectively to the keying action of people HER2 positive breast cancer cells

One, experimental technique

Human breast carcinoma HER2 overexpression cell line SKBR3 is suspended in the RPMI1640 nutrient solution containing 10% heat-inactivated fetal bovine serum, is inoculated in three confocol capsules with the density of 3000-5000/ware.Cultivate after 24 hours, substratum in exhaustion capsule, then the substratum 200 μ L of SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 polypeptide of the 50 μMs of ol/L marked containing fluorescein isothiocyanate (FITC) is added respectively, control group is with containing the substratum with the PBS (phosphoric acid buffer pH7.4) of polypeptide equivalent, nucleus hoechst reagent dyeing, uses and dilutes according to 1:200.Lucifuge ice bath hatches 30 minutes.PBS cleans, and after repeating to wash 3 times, adds 200 μ LPBS, uses laser confocal microscope observation fluorescent signal.

Two, experimental result

As seen from Figure 3, SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 peptide can act on the surface of people HER2 positive breast cancer cells, illustrate that peptide of the present invention is used alone and has keying action to HER2 positive tumor cell, can use as the polypeptide of target HER2.

Experimental example 4 immunofluorescence method detects SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 respectively to the Normocellular keying action of the negative embryonic kidney of people HER2

One, experimental technique

HER2 negative human embryo kidney (HEK) normal cell strain 293A is suspended in the H-DMEM nutrient solution containing 10% heat-inactivated fetal bovine serum, is inoculated in three confocol capsules with the density of 3000-5000/ware.Cultivate after 24 hours, substratum in exhaustion capsule, then the substratum 200 μ L of SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 polypeptide of the 50 μMs of ol/L marked containing fluorescein isothiocyanate (FITC) is added respectively, control group is with containing the substratum with the PBS (phosphoric acid buffer pH7.4) of polypeptide equivalent, nucleus hoechst reagent dyeing, uses and dilutes according to 1:200.Lucifuge ice bath hatches 30 minutes.PBS cleans, and after repeating to wash 3 times, adds 200 μ LPBS, uses laser confocal microscope observation fluorescent signal.

Two, experimental result

As seen from Figure 4, SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 peptide is not combined with the negative embryonic kidney normal cell of people HER2, illustrate that peptide of the present invention is selectivity specific binding to HER2 positive tumor cell, can use as the polypeptide of special target HER2.

Experimental example 5 surface plasma resonance (SPR) method detects SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 respectively to the avidity of people HER2 albumen

One, experimental technique

By SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 peptide of 1mg/mL and 0.01mMPBS point on chip, overnight incubation under 4 DEG C of wet condition, then ten minutes are cleaned with 0.1mMPBS, 0.01mMPBS cleans ten minutes, finally use washed with de-ionized water ten minutes, and repeat once, immerse in the 0.01mMPBS containing 5% milk, overnight incubation under 4 DEG C of conditions, then clean ten minutes with 0.1mMPBS, 0.01mMPBS cleans ten minutes, finally use washed with de-ionized water ten minutes, and repeat once, to dry up with nitrogen, upper machine.Moving phase passes through the people HER2 albumen of 1.25 μ g/mL, 2.5 μ g/mL, 5 μ g/mL, 10 μ g/mL and 20 μ g/mL successively, record analysis spr signal.

Two, experimental result

As seen from Figure 5, the spr signal of SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 peptide strengthens gradually along with the increase of people HER2 protein concentration, calculates the dissociation constant K of SEQIDNO.1, SEQIDNO.2, SEQIDNO.3 and SEQIDNO.4 polypeptide to HER2 albumen according to SPR result _dvalue is respectively: 1.86 × 10 ^-8m/L, 8.12 × 10 ^-8m/L, 9.06 × 10 ^-8m/L, 2.67 × 10 ^-7m/L, illustrates that polypeptide of the present invention has strong keying action to HER2, can use as the polypeptide of target HER2.

The result of experimental example 1-5 shows, on a cellular level, it is specially to be combined with the breast cancer cell of the HER2 positive that flow cyctometry and immunofluorescence technique two kinds of experiment tests all show SEQIDNO.1, SEQIDNO.2, SEQIDNO.3 and SEQIDNO.4 polypeptide, and be incorporated into the surface of cell membrane of HER2 protein expression, and be not obviously combined with the embryonic kidney normal cell of HER2 feminine gender; On a molecular scale, surface plasma resonance (SPR) experiment confirms that SEQIDNO.1, SEQIDNO.2, SEQIDNO.3, SEQIDNO.4 polypeptide all has strong keying action with HER2 albumen too, and along with the raising of HER2 protein concentration, binding signal is stronger.

Can draw from experimental example 1-5, polypeptide of the present invention has the characteristic of target HER2 positive tumor cell, thus in actual applications, can using peptide of the present invention as target polypeptide, put together mutually with the preparation that can kill and wound cancer cells or mix, for the targeted therapy of tumour, or can put together mutually with photographic developer or mix, for molecular imaging and the diagnosis of target tumor.

Applicant states, the present invention illustrates processing method of the present invention by above-described embodiment, but the present invention is not limited to above-mentioned processing step, does not namely mean that the present invention must rely on above-mentioned processing step and could implement.Person of ordinary skill in the field should understand, any improvement in the present invention, to equivalence replacement and the interpolation of ancillary component, the concrete way choice etc. of raw material selected by the present invention, all drops within protection scope of the present invention and open scope.

Claims

1. a peptide for special target HER2 albumen, is characterized in that, the general formula of described polypeptide is:

X ₁X ₂X ₃X ₄X ₅LX ₆X ₇X ₈NPX ₉X ₁₀X ₁₁X ₁₂X ₁₃

Wherein, L is leucine, and N is l-asparagine, and P is proline(Pro), X _1-13for variable amino-acid residue;

Preferably, X ₁be charge residue residue, be preferably Methionin or aspartic acid; X ₂be polar amino acid residues, be preferably Methionin, Threonine or tyrosine; X ₃be aromatic series or aliphatic amino acid residue, be preferably phenylalanine or Isoleucine; X ₄be aromaticity or heterocyclic amino acid residue, be preferably tyrosine or proline(Pro); X ₅be aromaticity or heterocyclic amino acid residue, be preferably tyrosine or proline(Pro); X ₆be aliphatic amino acid residue, be preferably glycine or L-Ala; X ₇be aliphatics or aromatic amino acid residue, be preferably leucine, tyrosine or tryptophane; X ₈be aromatic amino acid residue, be preferably tyrosine or tryptophane; X ₉be polar amino acid residues, be preferably Threonine or l-asparagine; X ₁₀be polar amino acid residues, be preferably Threonine or L-glutamic acid; X ₁₁be aromatic amino acid residue, be preferably tyrosine or tryptophane; X ₁₂be aromaticity or polar amino acid residues, be preferably phenylalanine, arginine or glutamine; X ₁₃aromaticity or polar amino acid residues, be preferably tyrosine, Methionin or glutamine.

2. peptide according to claim 1, is characterized in that, the aminoacid sequence of described peptide is selected from the aminoacid sequence shown in one of SEQIDNO.1-SEQIDNO.59.

3. a DNA fragmentation, is characterized in that, it comprises the nucleotide sequence of peptide described in any one of coding claim 1-2.

4. an expression vector, is characterized in that, described expression vector contains the DNA fragmentation as claimed in claim 3 of at least one copy.

5. a host cell, is characterized in that, described host cell contains expression vector according to claim 4.

6. the bivalent that the peptide according to any one of claim 1-2 is formed or multivalent, it is characterized in that, described bivalent or multivalent have the characteristic of target HER2 positive tumor cell and have lethality to tumour cell;

Preferably, described bivalent or multivalent are by connecting molecule and/or the covalently bound formation of polymkeric substance;

Preferably, described bivalent or multivalent be by be connected molecule and/or mixed with polymers, non-covalent linking formed;

7. a pharmaceutical composition, is characterized in that, described pharmaceutical composition comprises the peptide according to any one of claim 1-2 and can kill and wound the preparation of cancer cells;

Preferably, described pharmaceutical composition comprises bivalent according to claim 6 or multivalent and can kill and wound the preparation of cancer cells;

Preferably, described peptide, bivalent or multivalent, as target polypeptide, are puted together mutually with the preparation that can kill and wound cancer cells or mix;

Further preferably, described preparation is any one in alkylating agent, antimetabolite, antitumor natural drug, antitumor antibiotics, hormone, metal complex or tumour radiotherapy target marker;

8. a pharmaceutical composition, is characterized in that, described pharmaceutical composition comprises peptide described in any one of claim 1-2 and video picture preparation;

Preferably, described pharmaceutical composition comprises bivalent according to claim 6 or multivalent and video picture preparation;

Preferably, described peptide, bivalent or multivalent are puted together mutually with video picture preparation or are mixed;

9. any one of claim 1-2 or peptide according to claim 6, bivalent or multivalent for the preparation of the purposes in treatment, prevention or the medicine of diagnosing cancer or video picture preparation.

10. purposes according to claim 9, is characterized in that, described cancer is the cancer of HER2 process LAN;

Preferably, described cancer is any one in mammary cancer, lung cancer, cancer of the stomach, liver cancer, colon and rectum carcinoma, the esophageal carcinoma, leukemia, bladder cancer or cervical cancer or nasopharyngeal carcinoma.